Operating profit before deduction of amortization: Protagonist (PTGX)
Protagonist Therapeutics adheres to basic environmental standards when developing immune therapies, which is reflected in the change in its EBITDA. The current level of this metric is 321.49. Peptide development remains independent of macroeconomics and recessions, while AI accelerates molecular modeling, although final tests remain the responsibility of physicians.
Protagonist (PTGX) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Debt to Capital|Current Liabilities to Capital Protagonist Therapeutics, Inc.|PTGX - Company Debts|Debts to Book Capitalization Ratio Protagonist Therapeutics|PTGX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Protagonist Therapeutics|Immediate Liquidity protagonist-inc.com
- earnings and multiples data:
PTGX - Net Income|Future Net Profit Protagonist Therapeutics|PTGX - P/E Multiple|Forward P/E Multiple protagonist-inc.com|PTGX - PEG Multiple|Enterprise Value to EBITDA Multiple Protagonist Therapeutics|PTGX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Protagonist Therapeutics|PTGX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months protagonist-inc.com|PTGX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Protagonist Therapeutics
Analysis of all company metrics:Protagonist Corp, PTGX
This indicator captures the net cash flow from operating activities, allowing for an assessment of the operating cycle's efficiency and the business's resilience to production costs. By analyzing the distribution of EBITDA across periods, an investor can discern the actual ability of Protagonist Therapeutics (PTGX) to generate income, which in the current model is supported by strategic financing and commercial backing from a major pharmaceutical partner.
Competitors of Protagonist Therapeutics (PTGX)
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Immunovant Inc|Operating profit before deduction of amortization KNSA|Operating profit EBITDA Grifols Biemat|Profit before payment of interest, taxes and amortization Adaptive Biotechnologies (ADPT)|celldex.com - Operating profit before amortization|Operating profit EBITDA AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Profit before interest, taxes and amortization|VERA - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization DNTH|Pharvaris N.V. (PHVS) - Profit before payment of interest, taxes and amortization|AbCellera - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tourmaline Bio|Profit before interest, taxes and amortization Precigen Inc PGEN|Operating profit before deduction of amortization PHAR (Pharming)|Company profit before taxes, interest and amortization NKTR|Operating profit EBITDA UPB (Upstream Bio Inc)|Operating profit EBITDA zenasbio.com ZBIO|Immunome - Operating profit EBITDA|Operating profit before depreciation charges Gossamer Bio Inc (GOSS)|KalVista Pharmaceuticals Inc (KALV) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Septerna Pharma (SEPN)|Profit before payment of interest, taxes and amortization Pieris Pharmaceuticals|Operating profit before amortization SVRA (savarapharma.com)|Operating profit EBITDA RIGL|Operating income before deduction of amortization AnaptysBio Inc|Profit before payment of interest, taxes and amortization Astria Pharma ATXS|Operating income before deduction of amortization enGene Corp (ENGN)|RAPT: Operating profit before deduction of amortization|Aerovate Therapeutics Inc - Company profit before taxes, interest and amortization|ACRS (Aclaris Therapeutics, Inc.) - Operating profit before deduction of amortization|Kyverna Therapeutics Inc. - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization TLSA|CABA (Cabaletta Bio Inc) - Company profit before taxes, interest and amortization|Operating profit EBITDA VTYX|THTX (theratech.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA AVTX (Avalo Therapeutics)|Eledon Pharmaceuticals Inc. (ELDN) - Profit before interest, taxes and amortization|AGEN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CLYM (Climb Bio, Inc)|ZURA: Operating profit EBITDA|atyrpharma.com (ATYR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Adagene Inc|Ikena Oncology, Inc. - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA STTK|EQ - Profit before interest, taxes and amortization|Connect Biopharma Holdings Limited - Operating profit before deduction of amortization|Operating profit EBITDA Immunic Therapeutics IMUX|ATRA: Operating profit before deduction of amortization|InflaRx N.V. - Company profit before taxes, interest and amortization|XFOR: Operating profit EBITDA|ACET - Operating income before deduction of amortization|CELU (Celularity Inc) - Operating profit EBITDA|Operating profit before deduction of amortization inmunebio.com (INMB)|Profit before payment of interest, taxes and amortization Barinthus Biotherapeutics plc (BRNS)|Operating income before deduction of amortization Kezar Life Sciences Inc.|Profit before payment of interest, taxes and amortization SAB Biotherapeutics, Inc SABS|AKTX (Akari Therapeutics, Plc) - Profit before deduction of interest, taxes, depreciation and amortization|ENLV: Operating profit before deduction of amortization|Q32 Bio Inc. - Company profit before taxes, interest and amortization|GOVX: Operating profit EBITDA|Operating profit before depreciation charges Edesa Biotech Inc EDSA|Operating profit before deduction of amortization IBIO|Operating profit before amortization CARM (Carisma Tx)|Profit before payment of interest, taxes and amortization XTL Biopharmaceuticals (XTLB)|BOLT: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA HCWB (HCW Biologics)|Income before deduction of interest, taxes and amortization APVO|AIM ImmunoTech Inc. - Operating profit EBITDA|ADTX - Operating profit EBITDA|GRI Bio, Inc. (GRI) - Profit before payment of interest, taxes and amortization|xortx.com - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Vyome Holdings|Operating profit before deduction of amortization Revelation Biosciences Inc (REVB)|Operating profit EBITDA INDP|Operating profit EBITDA BiondVax Pharmaceuticals (SCNI)|CalciMedica - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AFMD|Allakos Therapeutics - Operating profit EBITDA|Operating income before deduction of amortization HOOKIPA Pharma Inc. HOOK|igmbio.com (IGMS) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization iTeos Pharma|Profit before payment of interest, taxes and amortization Ocean Biomedical, Inc.|Operating profit before deduction of amortization tcbiopharm.com (TCBP)|Operating profit before deduction of amortization THRD (Third Harmonic Bio, Inc.)
